PATH vs PRLD
Uipath Inc (PATH) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the PATH and PRLD stock pages for the full models.
Not investment advice.